Latest revenue
$6.6M
as of 2025-12-31
Latest net income
$-63.2M
as of 2025-12-31
Net margin
-957.7%
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ANRO is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $638.2M
- Enterprise value
- $392.8M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 2.62×
- Dividend yield
- 0.0%
- 52-wk high
- $28.44
- 52-wk low
- $2.15
- Beta
- —
- Shares out
- 35.1M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1. Business. Overview We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Through insights derived from our scalable and proprietary Precision Psychiatry Platform, or our Platform, we aim to discover brain-based biomarkers to better identify which patients are more likely to respond to our novel product candidates. Our current pipeline consists of seven clinical-stage assets addressing high-need therapeutic areas, including major depressive disorder, or MDD, bipolar depression, or BPD, treatment resistant depression, or TRD, schizophrenia, and Parkinson’s…
AI summary unavailable — showing raw filing excerpt
Generated from ANRO's filing dated 2026-03-16
Key risks
Table of Contents Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Annual Report, including our consolidated financial statements and their related notes included elsewhere in this Annual Report and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” before making an investment decision. If any of the following risks actually occurs, our business, prospects, operating results, and financial condition could suffer materially, the trading price of our common stock could…
AI summary unavailable — showing raw filing excerpt
Generated from ANRO's filing dated 2026-03-16
Profitability
Operating margin
-1005.1%
29.7%Net margin
-957.7%
38.0%Return on equity
-41.8%
148.7%Return on assets
-34.2%
1.0%Leverage
Debt / equity
0.22×
106.3%Long-term debt / equity
0.11×
174.6%Debt / assets
18.0%
87.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-26.2M | -73.0% | — |
Q4 2025 2025-12-31 | — | — | $-16.2M | -6.5% | — |
Q3 2025 2025-09-30 | — | — | $-14.2M | +15.5% | — |
Q2 2025 2025-06-30 | — | — | $-17.7M | -10.5% | — |
Q1 2025 2025-03-31 | — | — | $-15.2M | -13.1% | — |
Q4 2024 2024-12-31 | — | — | $-15.2M | — | — |
Q3 2024 2024-09-30 | — | — | $-16.8M | -83.6% | — |
Q2 2024 2024-06-30 | — | — | $-16.0M | -85.0% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ANRO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ANRO
Institutional value
$90.9M
Total shares held
4.1M
Distinct holders
43
-55 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $27.1M | — | New |
| 2 | FRANKLIN RESOURCES INC | 1.1M | $24.8M | -17.7K (-1.6%) | Trimmed |
| 3 | BlackRock, Inc. | 666.2K | $15.0M | +58.3K (+9.6%) | Added |
| 4 | JENNISON ASSOCIATES LLC | 386.4K | $8.7M | — | New |
| 5 | VANGUARD FIDUCIARY TRUST CO | 165.3K | $3.7M | — | New |
| 6 | STIFEL FINANCIAL CORP | 86.3K | $1.9M | -829 (-1.0%) | Trimmed |
| 7 | TD ASSET MANAGEMENT INC | 43.8K | $984.6K | — | New |
| 8 | Hudson Bay Capital Management LP | 43.8K | $983.8K | +9.0K (+25.8%) | Added |
| 9 | AdvisorShares Investments LLC | 41.0K | $922.2K | -3.1K (-6.9%) | Trimmed |
| 10 | DIMENSIONAL FUND ADVISORS LP | 39.3K | $884.0K | +8.1K (+26.1%) | Added |
| 11 | JANE STREET GROUP, LLC | 30.1K | $675.7K | -164.0K (-84.5%) | Trimmed |
| 12 | Allianz Asset Management GmbH | 28.5K | $640.7K | -14.5K (-33.7%) | Trimmed |
| 13 | ALPS ADVISORS INC | 25.3K | $568.5K | -217 (-0.9%) | Trimmed |
| 14 | Y-Intercept (Hong Kong) Ltd | 23.9K | $538.3K | — | New |
| 15 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 22.2K | $498.5K | +0 (+0.0%) | No change |
| 16 | LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 18.1K | $406.5K | — | New |
| 17 | UBS Group AG | 17.3K | $387.8K | -1.2K (-6.7%) | Trimmed |
| 18 | Revisor Wealth Management LLC | 17.1K | $385.1K | — | New |
| 19 | SCS Capital Management LLC | 16.8K | $378.6K | -16.5K (-49.6%) | Trimmed |
| 20 | Clearstead Advisors, LLC | 13.3K | $299.3K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ANRO's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.